TML-6

• Description:

  TML-6, an orally active curcumin derivative, inhibits the synthesis of the β-amyloid precursor protein and β-amyloid (Aβ) . TML-6 can upregulate Apo E, suppress NF-κB and mTOR, and increase the activity of the anti-oxidative Nrf2 gene. TML-6 has the potential for Alzheimer’s disease (AD) research[1].

• UNSPSC:

  12352005

• Target:

  Amyloid-β; Keap1-Nrf2; mTOR; NF-κB

• Type:

  Reference compound

• Related Pathways:

  Neuronal Signaling; NF-κB; PI3K/Akt/mTOR

• Applications:

  Neuroscience-Neurodegeneration

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/tml-6.html

• Purity:

  99.01

• Solubility:

  DMSO : 120 mg/mL (ultrasonic)

• Smiles:

  O=C(N(CC)CC)CC(C)(C(/C=C/C1=CC=C(OC)C(OC)=C1)=O)C(/C=C/C2=CC=C(OC)C(OC)=C2)=O

• Molecular Formula:

  C30H37NO7

• Molecular Weight:

  523.62

• References & Citations:

  [1]Ih-Jen Su, et al. A Curcumin Analog Exhibits Multiple Biologic Effects on the Pathogenesis of Alzheimer's Disease and Improves Behavior, Inflammation, and β-Amyloid Accumulation in a Mouse Model. Int J Mol Sci. 2020 Jul 30;21 (15) :5459.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  MTOR; NF-κB

• CAS Number:

  [1462868-88-7]